A Randomized, Phase 2a, Partially-Blind, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naive Subjects With Chronic Hepatitis C
Phase of Trial: Phase II
Latest Information Update: 02 Nov 2017
At a glance
- Drugs VX 135 (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Alios BioPharma
- 30 Oct 2013 Results were reported in a Vertex Pharmaceuticals media release.
- 30 Oct 2013 Status changed from active, no longer recruiting to completed, as reported in a Vertex Pharmaceuticals media release.
- 30 Jul 2013 According to a Vertex media release, dosing has been completed in this trial. Results are anticipated later this year.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History